---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-057018"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:58:31.069005+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics Reports Q1 2024 Net Loss of $5.1M and Cash of $36.0M, Advances Pipeline

## Summary
- Net loss was $5.1M for Q1 2024 vs $2.7M in Q1 2023; R&D expenses rose to $3.1M from $1.2M.
- Cash and cash equivalents totaled $36.0M as of March 31, 2024, providing runway into 2026.
- IND filing for COYA 302 in ALS expected in 2Q24, with Ph. 2 trial initiation thereafter.
- Pipeline expanded to include Frontotemporal Dementia, Parkinson’s, and Alzheimer’s diseases.
- Licensed next-generation immune modulatory biologics from University of Nebraska Medical Center in Feb 2024.

## SEC filing metadata
- accession: 0000950170-24-057018
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000095017024057018/0000950170-24-057018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000095017024057018/coya-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-057018
- JSON: https://secwatch.observer/filing/0000950170-24-057018.json
- Plain text: https://secwatch.observer/filing/0000950170-24-057018.txt

## Key facts
- Earnings Releases
  Coya Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss was $5.1 million for the three months ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Net income: Net loss was $5.1 million for the three months ended March 31, 2024
  - Result: reported results
  source text: Net loss was $5.1 million for the three months ended March 31, 2024, compared to net loss of $2.7 million for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000095017024057018/0000950170-24-057018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.